Safety of the combination of oral anticoagulant and antiplatelet therapy in cardiovascular disease: a meta-analysis by Verheugt, F.W.A.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/22948
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
JACC February 1996 ABSTRACTS - Poster 133 A
Results: Inhibition of 5 /¿M A DP-induced platelet aggregation showed a 
trend towards a dose-relationship over the dose-range tested. Bleeding time 
prolongation factor never exceeded 2. Tolerance was good at all doses 
tested.
Conclusion: In this multicenter dose-range study in atherosclerotic patients, 
clopidogrel demonstrated a dose-related activity. The dose of 75 mg once 
daily was chosen for the phase 111 international study CAPRIE (Clopidogrel 
vs. Aspirin in Patients at Risk of Ischemic Events) currently on-going in over 
19,000 patients.
Safety of the Combination of Oral Anticoagulant 
and Antiplatelet Therapy in Cardiovascular 
Disease: A Meta-Analysis
Freek W.A. Verheugt. Department of Cardiology, University Hospital 
Nijmegen, Nijmegen, The Netherlands
Both oral anticoagulant (AC) and antiplatelet (AP) therapy are effective in 
reducing mortality In patients (pis) with cardiovascular disease. The outcome 
of the trials of combined AC/AP compared to AC alone, AP alone or placebo 
is promising, but its safety is a matter of concern.
In the 6 published trials of combined AC/AP directly comparing reference 
therapy (AC, AP or placebo) 4,874 pts were randomized. High intensity AC 
(AC) INR > 2.5 was combined with high (> 500 mg aspirin qd) dose AP (AF) 
in 3 trials, and with low (< 100 mg aspirin qd) dose AP (ap) in 2 trials. Low 
intensity AC (ac) INR < 2.5 was combined with ap in 4 trials, Major bleeding 
(95% Cl):
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Thus, combined low intensity oral anticoagulant/low dose aspirin therapy 
shows the lowest major bleeding (5/100 pt yrs), not significantly different from 
low intensity oral anticoagulant therapy alone, This combination therapy now 
undergoes large scale evaluation of clinical efficacy and safely.
Enhanced Coronary Vasoconstriction to 
Endothelin-B Receptors Activation in Experimental 
Congestive Heart Failure
Charles R. Cannan, John C. Burnett Jr., Amir Lerman. Mayo Clinic, 
Rochester, MN
Thoracic inferior vena cava constriction (TIVCC) is an experimental model of 
heart failure characterized by a decrease in cardiac output and an increase 
in plasma endothelin (ET) concentrations. ET, a coronary vasoconstrictor, 
mediates its activity through two specific receptors (ET-A and ET-B), which 
demonstrate different activity levels in pathophysiological conditions. The 
current study was designed to test the hypothesis that experimental heart 
failure is characterized by an enhanced coronary vasoconstriction to the ET- 
B receptors activation. Sarafotoxin (an ET-B receptor agonist) at 2 ng/kg/min 
was infused into the left circumflex coronary artery in normal (n = 5) and 
TIVCC (n = 5) anesthetized dogs. Plasma ET was elevated in the TIVCC 
dogs as compared to the Normal group (37 ±  5 vs. 17 ±  3, p < 0.05)
Normal TIVCC
% A CBF -7  ± 8 -31 ± 4*
% A CVR 12±8 53 dr 12*
% A CAD 1.9 ±0,7 2.1 ±1.9
%A from baseline, CBF = coronary blood flow, CVR = coronary vascular resistance, CAD 
= coronary artery diameter; *p < 0.05 between normal vs. TIVCC.
These studies demonstrate an enhanced coronary vasoconstrictor re­
sponse to sarafotoxin in experimental heart failure which is chiefly localized 
to the microcirculation. This study suggests an alteration in coronary ET-B 
receptor activity in heart failure and underscores the importance of the ET-B 
receptors in the control of coronary vascular tone this condition.
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What Should Be the Goal of LDL-Cholesterol 
Lowering in Coronary Patients; a Fixed Level or a 
Percent Reduction?
David Waters, Justine Hollyer, Gilbert R. Thompson. Hartford Hospital, 
Hartford, CT; Hammersmith Hospital, London, UK
NCEP guidelines stipulate that LDL-cholesterol (LDL-C) should be reduced to 
the same level in all coronary patients, to < 100 mg/dl. But a recent secondary 
analysis of the 4S data showed that the decrease in LDL-C with simvastatin 
(32-37%) and the decrease in relative risk (32-36%) were comparable 
across atl quartiles of baseline LDL-C, despite differences in on-trial LDL-C 
(Lancet 1995;345:1274). To test the hypothesis that the reduction in LDL-C 
correlates better with outcome than the on-treatment level of LDL-C, we ex­
amined the 24 control and treatment groups from the 11 cholesterol-lowering 
coronary angiographic trials (FATS, SCOR, STARS, Lifestyle, MARS, CCAIT, 
HARP, SCRIP, MAAS, FHRS and PLAC-1) with quantitative measurements 
of lesion percent diameter stenosis change (A%DS). Mean A%DS ranged 
from +5.8 (progression) to -2 .5  (regression), mean on-trial LDL-C varied 
from 86 to 242 mg/dl and change in LDL-C ranged from +3% to -53%. Lin­
ear regression analysis was performed with the groups weighted according 
to their size.
Results: The relationship between on-trial LDL-C levels and A%DS was 
weak: r = 0.36, p = 0.086. However, a strong relationship was seen between 
% change in LDL-C and A%DS (A%DS = 3.18 + 0.071 x %ALDL-C; r = 
0.74, p < 0.0005). According to the equation, a 44% reduction of LDL-C is 
needed to arrest coronary progression.
Conclusions: Reducing LDL-cholesterol by a percentage from the baseline 
level appears to be a more reasonable goal in coronary patients than aiming 
for the same target level in all. The emphasis on target levels in the current 
guidelines seems open to question.
Physician Compliance With National Cholesterol 
Education Panel Guidelines in Patients With 
Myocardial Infarction
Ori Ben-Yehuda, Parul Desai, Daniel G. Blanchard. University of California, 
San Diego, CA
Lowering elevated LDL-Cholesterol (LDL-C) in patients with documented 
CAD reduces morbidity and mortality. NCEP guidelines in this population 
are based on LDL-C levels, with a target level of < 100 mg/dl. In order to 
assess physician compliance with NCEP guidelines, we reviewed the care 
of all patients under 75 years of age discharged with the diagnosis of acute 
Ml in 1994 in our institution. Mean follow-up was 9.6 db 0.8 months (range 
4— 15).
Of 114 patients with the diagnosis of acute Ml, 30 (26%) had known hyper 
LDL-C prior to their Ml. Of these only 6/30 (20%) had documented LDL-C in 
the target range on follow-up. In 7/30 (23%) no therapy was instituted, while in 
17/30 (57%) target LDL-C level was either not achieved or not documented.
Of the 84 patients (74%) without known hyperlipidemia, six had evaluation 
and therapy per NCEP guidelines. An incomplete evaluation (only total-C or 
profile obtained during acute illness) was performed in 44/84 (52%) while 
16/84 (19%) had no iipid evaluation at all. No therapy was instituted in 18/84 
(21%) who met NCEP criteria for therapy.
Overall, only 12/114 (11%) patients were evaluated according to NCEP 
guidelines and had documentation of achieving treatment goals. In contrast, 
100% of patients were prescribed ASA (p < 0.001), another recommended 
therapy in patients with CAD.
Thus physician compliance with NCEP guidelines in this study was low, 
with most patients not having LDL-C based evaluation and therapy. Greater 
effort has to be made in educating physicians in lipid management post Ml.
Should Lipid-Lowering Drugs Be Part of Initial 
Therapy in the Secondary Prevention of CHD?
Christie M. Baliantyne, M. Stewart West, Suzanne M. Jaax, Lynne W. Scott, 
J. Alan Herd, Peter H. Jones, John A. Farmer, Antonio M. Gotto, Jr.. Baylor 
College of Medicine, Houston, TX
The 1993 NCEP recommends that dietary therapy (Step II Diet) be tried for 
up to 12 wk in drug-eligible adults with CHD to achieve their LDL-C goal of 
< 100 mg/dL; drugs are considered when LDL-C > 130 mg/dL persists. We 
used enrollment screening data from the secondary-prevention Lipoprotein
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